Arcus Biosciences, Inc.

RCUS · NYSE
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$135,000$0-$112,000-$94,000
Dep. & Amort.$2,000$2,000$3,000$3,000
Deferred Tax$0$0$0$0
Stock-Based Comp.$14,000$0$16,000$17,000
Change in WC$21,000-$148,000-$37,000-$23,000
Other Non-Cash$1,000$13,000-$2,000-$3,000
Operating Cash Flow-$97,000-$133,000-$132,000-$100,000
Investing Activities
PP&E Inv.$0$0-$1,000-$1,000
Net Acquisitions$0$0$0$0
Inv. Purchases-$165,000-$161,000-$353,000-$172,000
Inv. Sales/Matur.$244,000$298,000$386,000$224,000
Other Inv. Act.$0$0$0$0
Investing Cash Flow$79,000$137,000$32,000$51,000
Financing Activities
Debt Repay.$0$49,000$0$0
Stock Issued$8,000$3,000$142,000$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0-$2,000
Financing Cash Flow$8,000$52,000$142,000-$2,000
Forex Effect$0$0$0$0
Net Chg. in Cash-$10,000$56,000$42,000-$51,000
Supplemental Information
Beg. Cash$251,000$192,000$153,000$204,000
End Cash$241,000$248,000$195,000$153,000
Free Cash Flow-$97,000-$133,000-$133,000-$101,000